High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone

British Journal of Haematology

Volumn 161, Issue 5, 2013, Pages 695-700

  Heintel, Daniel ^a   Rocci, Alberto ^b   Ludwig, Heinz ^a   Bolomsky, Arnold ^a   Caltagirone, Simona ^b   Schreder, Martin ^a   Pfeifer, Sabine ^a   Gisslinger, Heinz ^c   Zojer, Niklas ^a   Jäger, Ulrich ^c   Palumbo, Antonio ^b  

^a WILHELMINEN HOSPITAL   (Austria)

^b UNIVERSITY OF TURIN   (Italy)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cereblon; Interferon regulatory factor 4; Lenalidomide; Multiple myeloma

Indexed keywords

BETA 2 MICROGLOBULIN; BETA CATENIN; DEXAMETHASONE; INTERFERON REGULATORY FACTOR 4; LENALIDOMIDE; SYNDECAN 1; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CEREBLON GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG RESPONSE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TUMOR GENE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CATENIN; BONE MARROW; DEXAMETHASONE; HUMANS; INTERFERON REGULATORY FACTORS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PEPTIDE HYDROLASES; PLASMA CELLS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84877807633     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12338     Document Type: Article

References (26)

1. Anderson, K.C. (2005) Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Seminars in Hematology, 42(4 Suppl. 4), S3-S8.
2. Bjorklund, CC., Ma, W., Wang, Z.Q., Davis, R.E., Kuhn, D.J., Kornblau, S.M., Wang, M., Shah, J.J. & Orlowski, R.Z. (2011) Evidence of a role for activation of Wnt/ß-catenin signaling in the resistance of plasma cells to lenalidomide. The Journal of Biological Chemistry, 13, 11009-11020.
3. Broyl, A., Kuiper, R., van Duin, M., van der Holt, B., El Jarari, L., Bertsch, U., Zweegman, S., Buijs, A., Hose, D., Lokhorst, H.M., Goldschmidt, H. & Sonneveld, P. (2012) High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood, 124, 624-627.
4. Chang, X.B. & Stewart, A.K. (2011) What is the functional role of the thalidomide binding protein cereblon? International Journal of Biochemistry and Molecular Biology, 2, 287-294.
5. Dimopoulos, M.A., Spencer, A., Attal, M., Prince, M.H., Harousseau, J.L., Dmoszynska, A., San Miguel, J., Hellmann, A., Facon, T., Foà, R., Corso, A., Masliak, Z., Olesnyckyj, R.N., Yu, Z., Patin, J., Zeldis, J.B. & Knight, R.D. (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. The New England Journal of Medicine, 357, 2123-2132.
6. Dimopoulos, M.A., Chen, C., Spencer, A., Niesvizky, R., Attal, M., Stadtmauer, E.A., Petrucci, M.T., Yu, Z., Olesnyckyj, M., Zeldis, J.B., Knight, R.D. & Weber, D.M. (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia, 23, 2147-2152.
7. Durie, B.G., Harousseau, J.L., Miguel, J.S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V., International Myeloma Working Group. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
8. Galustian, C. & Dalgleish, A. (2009) Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opinion on Pharmacotherapy, 10, 125-133.
9. H gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. Leukemia, 18, 756-762.
10. Heintel, D., Zojer, N., Schreder, M., Strasser-Weippl, K., Kainz, B., Vesely, M., Gisslinger, H., Drach, J., Gaiger, A., Jäger, U. & Ludwig, H. (2008) Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia, 22, 441-445.
11. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y. & Handa, H. (2010) Identification of a primary target of thalidomide teratogenicity. Science, 327, 1345-1350.
12. Ito, T., Ando, H. & Handa, H. (2011) Teratogenic effects of thalidomide: molecular mechanisms. Cellular and Molecular Life Sciences, 68, 1569-1579.
13. Klimowicz, A., Neri, P., Andrew Belch, A., Dean, M., Ren, L., Gratton, K., Slaby, J., Johnson, J., Duggan, P., Stewart, D.A. & Bahlis, N.J. (2012) High cereblon protein expression correlates with improved response and survival in myeloma patients treated with lenalidomide. Blood (ASH Annual Meeting Abstracts), 120, 931.
14. Lacy, M.Q. (2011) New immunomodulatory drugs in myeloma. Current Hematologic Malignancy Reports, 6, 120-125.
15. Li, S., Pal, R., Monaghan, S.A., Schafer, P., Ouyang, H., Mapara, M., Galson, D.L. & Lentzsch, S. (2001) IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood, 117, 5157-5165.
16. Lopez-Girona, A., Heintel, D., Zhang, L.H., Mendy, D., Gaidarova, S., Brady, H., Bartlett, J.B., Schafer, P.H., Schreder, M., Bolomsky, A., Hilgarth, B., Zojer, N., Gisslinger, H., Ludwig, H., Daniel, T., Jäger, U. & Chopra, R. (2011) Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. British Journal of Haematology, 154, 325-336.
17. Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A.K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., Mahmoudi, A., Cathers, B., Rychak, E., Gaidarova, S., Chen, R., Schafer, P.H., Handa, H., Daniel, T.O., Evans, J.F. & Chopra, R. (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, 26, 2326-2335.
18. Quach, H., Ritchie, D., Stewart, A.K., Neeson, P., Harrison, S., Smyth, M.J. & Prince, H.M. (2010) Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia, 24, 22-32.
19. Schey, S. & Ramasamy, K. (2011) Pomalidomide therapy for myeloma. Expert Opinion on Investigational Drugs, 20, 691-700.
20. Shaffer, A.L., Emre, N.C., Lamy, L., Ngo, V.N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., Zeng, Y., Chen, B., Epstein, J. & Staudt, L.M. (2008) IRF4 addiction in multiple myeloma. Nature, 454, 226-231.
21. Shaffer, A.L., Emre, N.C., Romesser, P.B. & Staudt, L.M. (2009) IRF4: immunity. Malignancy! Therapy?. Clinical Cancer Research, 15, 2954-2961.
22. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J., Siegel, D., Crowley, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565-1571.
23. Tageja, N. (2011) Lenalidomide - current understanding of mechanistic properties. Anti-cancer Agents in Medicinal Chemistry, 11, 315-326.
24. Vallet, S., Palumbo, A., Raje, N., Boccadoro, M. & Anderson, K.C. (2008) Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leukemia & Lymphoma, 49, 1238-1245.
25. Van Rhee, F., Dhodapkar, M., Shaughnessy, Jr, J.D., Anaissie, E., Siegel, D., Hoering, A., Zeldis, J., Jenkins, B., Singhal, S., Mehta, J., Crowley, J., Jagannath, S. & Barlogie, B. (2008) First thalidomide clinical trial in multiple myeloma: a decade. Blood, 112, 1035-1038.
26. Zhu, Y.X., Braggio, E., Shi, C.X., Bruins, L.A., Schmidt, J.E., Van Wier, S., Chang, X.B., Bjorklund, C.C., Fonseca, R., Bergsagel, P.L., Orlowski, R.Z. & Stewart, A.K. (2011) Cereblon expression is required for the anti-myeloma activity of lenalidomide and pomalidomide. Blood, 118, 4771-4779.